This sequence click here coverage lends insight into the complex proteins being studied. A high percentage of sequence coverage indicates that there are few PTMs associated with the proteins, as well as no truncation. The presence of PTMs has been known to compromise protein identification, and truncated proteins do not function as expected. In addition to providing enhanced sequence coverage, the use of data-independent MSE analysis and label-free quantification software allowed us to relatively quantify the amount of each protein present in the BoNT/G complex (Table 2). This quantification
method has the advantage of being able to provide accurate estimates of relative protein abundance (often within 30% of the known values on most identified proteins in a mixture, without the much more rigorous requirements of targeted protein quantification methods. A percentage of abundance (by weight and molecules, separately) of each protein within the complex was determined, as well as an HDAC inhibitor overall weight ratio of BoNT:NAPs and a molecular ratio of BoNT:NTNH:HA70:HA17. Analysis of the individual proteins within the complex illustrated that the weight of the toxin (30.4%) is almost equivalent to that of HA70 (27.8%) and about eight percent less than that of NTNH (38%); whereas HA17 makes up
only a minute portion of the overall weight at just 3.7%. Conversely, analysis using molecular amounts indicated that the complex contains an equivalent amount of the toxin, NTNH, and HA17, whereas HA70 is almost twice as abundant. The nanogram and
BMS202 femtomole on column data sets signify a likely overall ratio of 1:3 BoNT:NAPs weight ratio and a 1:1:2:1 BoNT:NTNH:HA70:HA17 molar ratio. As stated earlier, the function of the NAPs has been shown to protect the neurotoxin in harsh environments [12]. Due to this protective ability, in theory, a larger ratio of NAPs:BoNT, ie the greater the number of molecules of NAPs to (-)-p-Bromotetramisole Oxalate BoNT, would protect more effectively the toxin from the acidic environment of the stomach. This potentially would increase the toxin’s effectiveness at penetrating the mucosa of the intestine and entering the blood stream, increasing the toxin’s chances of entering the synaptic cell and causing disease. Knowledge of the stoichiometry of proteins within the BoNT complexes would be useful to further understanding of NAPs significance and toxin potency. Conclusions We have presented a detailed in silico comparison of the/G complex of proteins to the other six serotypes in an effort to compare, contrast, and further define the complex’s relationship relative to the/B serotype and subtypes within the botulinum toxins. Proteomic analyses, consisting of gel electrophoresis, in gel and in solution digestions, and Endopep-MS, confirmed the presence of BoNT, NTNH, HA70, and HA17 proteins and the activity of the commercial/G complex.